. Author manuscript; available in PMC: 2022 Oct 26.

Published in final edited form as: Adv Funct Mater. 2020 Dec 4;31(44):2008701. doi: 10.1002/adfm.202008701

Table 1.

Summary of hydrogel-based drug delivery system (applied at RW unless indicated) development pipeline.

Product/description	Active agent	Polymer	Indication	Status
IGF-1	Insulin-like growth factor	Gelatin	SNHL	Clinical trial
OTIPRIO^a)	Ciprofloxacin	Poloxamer 407	Otitis media with effusion	FDA approved
OTIVIDEX	Dexamethasone	Poloxamer 407	Meniere’s Disease	Phase 3
OTO-311	NMDA receptor	Poloxamer 407	Tinnitus	Phase 1
OTO-413	Brain-derived neurotrophic factor	Undisclosed	Hidden hearing loss	Phase 1/2
OTO-510	Undisclosed otoprotectant	Undisclosed	Cisplatin-induced hearing loss	Pre-clinical
Pedmark	Sodium thiosulfate	None	Cisplatin-induced hearing loss	Phase 3
STR-001	Pioglitazone	Poloxamer 407	Hearing loss	Phase 3
Sonsuvi	Cell-penetrating peptide	Hyaluronic acid gel	SNHL or otitis media	Phase 3
Keyzilen	NMDA receptor antagonist	Hyaluronic acid gel	Acute inner ear tinnitus	Phase 3

SNHL, sensorineural hearing loss; NMDA, N-Methyl-D-Aspartate.

^a)

Applied in middle ear.